Abstract
KRAS has long been referred to as an ‘undruggable’ target due to its high affinity for its cognate ligands (GDP and GTP) and its lack of readily exploited allosteric binding pockets. Recent progress in the development of covalent inhibitors of KRAS\textsuperscript{G12C} has revealed that occupancy of an allosteric binding site located between the α3-helix and switch-II loop of KRAS\textsuperscript{G12C}—sometimes referred to as the ‘switch-II pocket’—holds great potential in the design of direct inhibitors of KRAS\textsuperscript{G12C}. In studying diverse switch-II pocket binders during the development of sotorasib (AMG 510), the first FDA-approved inhibitor of KRAS\textsuperscript{G12C}, we found the dramatic conformational flexibility of the switch-II pocket posing significant challenges toward the structure-based design of inhibitors. Here, we present our computational approaches for dealing with receptor flexibility in the prediction of ligand binding pose and binding affinity. For binding pose prediction, we modified the covalent docking program CovDock to allow for protein conformational mobility. This new docking approach, termed as FlexCovDock, improves success rates from 55 to 89% for binding pose prediction on a dataset of 10 cross-docking cases and has been prospectively validated across diverse ligand chemotypes. For binding affinity prediction, we found standard free energy perturbation (FEP) methods could not adequately handle the significant conformational change of the switch-II loop. We developed a new computational strategy to accelerate conformational transitions through the use of targeted protein mutations. Using this methodology, the mean unsigned error (MUE) of binding affinity prediction were reduced from 1.44 to 0.89 kcal/mol on a set of 14 compounds. These approaches were of significant use in facilitating the structure-based design of KRAS\textsuperscript{G12C} inhibitors and are anticipated to be of further use in the design of covalent (and noncovalent) inhibitors of other conformationally labile protein targets.

Keywords
Covalent docking · Pose prediction · Binding affinity · Free energy perturbation (FEP) · Switch-II pocket

Abbreviations
KRAS Kirsten rat sarcoma virus oncogene
GDP Guanosine diphosphate
GPU Graphics processing unit
GTP Guanosine triphosphate
API Application programming interface
FEP Free energy perturbation

MD Molecular dynamics
MMGB Molecular mechanics generalized Born approximation
MMGBSA Molecular mechanics generalized Born surface area
ns Nanosecond
RMSD Root mean squared deviation
MUE Mean unsigned error
SAR Structure–activity relationship
TI Thermodynamic integration

Introduction
KRAS is a G-protein that functions as a molecular switch regulating cellular proliferation in growth factor signaling pathways [1]. Mutations in KRAS impair the cycling of KRAS between its GTP-bound active state and GDP-bound
inactive state, leading to dysregulated cellular growth and oncogenesis. KRAS was identified as one of the first oncogenes in 1982 [2], but extensive research efforts over the following decades failed to provide clinically viable inhibitors of KRAS until the recent approval of sotorasib (3; AMG 510) in 2021 [3, 4].

Two factors contributed to the challenge in identifying inhibitors: (1) KRAS binds its native ligands, GDP and GTP, with picomolar affinity and high intracellular concentrations, making competitive inhibition challenging, and (2) other allosteric pockets on KRAS were either incompletely defined or lacked high-affinity ligands, posing challenges to the identification of allosteric inhibitors. In 2013, Shokat and colleagues [5] first reported the X-ray crystal structure of a covalent inhibitor bound to an engineered (‘cysteine-light’) version of the KRAS codon 12 mutant KRASG12C. This inhibitor bound in an allosteric pocket near the GDP binding site that the researchers termed the ‘switch-II pocket’ (and which had previously been referred to as the ‘P2 pocket’ [6] or ‘site 3’ [7]). This discovery, which built on an ongoing resurgence of interest in covalent inhibitors [8], was followed by multiple additional reports of covalent KRAS inhibitors targeting KRASG12C. In addition to sotorasib (3), which remains the only clinically approved KRASG12C inhibitor to date, eleven other covalent KRASG12C inhibitors targeting the switch-II pocket have now entered human clinical trials [9].

The switch-II pocket is a shallow pocket between the effector protein-engaging switch-II loop of KRAS (residues A59–Y64), the α2-helix (S65–T74), and the α3-helix (N86–K104, see Fig. 1) [10]. Upon ligand binding, this pocket undergoes significant conformational rearrangement [e.g., increasing in size from 150 to 280 Å³ in the case of sotorasib (3)]. This conformational change includes significant movement of the switch-II loop, a shift in position of the α2-helix, and side chain rotameric changes in many binding site residues. In work leading to the discovery of sotorasib (3), we found that the switch-II binding site proved to be highly flexible, with ligands binding to this pocket producing dozens of conformationally distinct poses, as illustrated in Fig. 1. This conformational flexibility posed a considerable challenge in using protein crystallographic data in the design and optimization of switch-II pocket-targeted covalent inhibitors of KRASG12C.

‘Docking’ is one of the most widely used computational tools for predicting ligand binding poses in drug discovery projects. Most docking methods have been developed to allow for full ligand flexibility in docking into a conformationally rigid receptor pocket. However, such an approach is ill-suited for the computational docking of switch-II pocket

![Fig. 1 Illustration of flexible residues in the switch-II binding pocket of KRASG12C. Receptor structures (10) from the cross-docking dataset are superimposed. All flexible residues in the FlexCovDock workflow are depicted in wire mode and five blocking residues (labeled) are shown in tube mode. In the right-hand panel, the switch-II loop is removed to reveal the two inside residues, R68 and M72](image-url)
ligands to KRAS, as the diverse range of switch-II pocket conformations observed with diverse ligands indicates that significant receptor flexibility must also be considered during docking calculations to ensure that relevant binding poses are identified and evaluated. Incorporation of receptor flexibility remains a challenge at the frontier of next generation docking method development [11, 12].

One common approach to addressing receptor conformational dynamics is ensemble docking, which runs multiple docking calculations with an ensemble of receptor structures [13, 14]. Appropriate structural ensembles are selected to encompass likely receptor conformational changes and can be generated from experimental structures, molecular dynamics simulations, or normal-mode analysis. The key to successful ensemble docking is the proper weighting of each structure to properly reflect its relative population [15]. Another common approach to incorporate receptor flexibility is to model receptor structural changes during the docking process, as is done in docking protocols such as AutoDockFR [16], IFD [17] and IFD-MD [18].

For covalent inhibitors, docking protocols must also deal with the added complexity of accounting for covalent bond formation between the ligand and target protein [19]. Many covalent docking protocols have been developed based on the conventional docking programs. For example, CovDock [20, 21] is a workflow utilizing the Glide docking protocol [22–24] and Prime protein structure refinement [25, 26]; DOCKvalent is a variation of DOCK [27]. AutoDock [28] natively supports covalent inhibitor docking, as do CovDockvalent [29] and WIDOCK [30], which are based on AutoDock.

There have been several reports of using covalent docking successfully in the virtual screening and lead optimization [27, 30–32]. However, to our knowledge, none of these covalent docking methods has the capability to deal with flexible receptors. In this work, we have modified CovDock, which has shown superior accuracy in binding pose prediction [20], to incorporate receptor flexibility, and have successfully used the modified protocol in the design and optimization of covalent inhibitors of KRASG12C.

Beyond simply complicating binding pose prediction, receptor flexibility also significantly complicates the accurate prediction of binding affinities. Several computational approaches have been developed to address this complexity. In docking calculations, ‘docking scores’ are frequently used to rank different poses while also providing an estimate of binding affinity derived from empirical functions capturing various binding energy components such as hydrophobic interactions and hydrogen bonds. Docking scores, however, have been shown to be more successful in predicting binding poses (i.e., ranking different poses for one compound) than in predicting binding affinities (i.e., ranking the relative binding affinities of different compounds) [33].
been published previously. These groups demonstrate distinct ligand flexibility profiles and receptor conformations and serve to illustrate the relative strengths and limitations of binding affinity prediction using docking score, MMGB, and FEP methodology. Analyzing these sets of compounds, we show that conventional FEP methodology works well on relatively rigid receptor pocket, but cannot adequately handle switch-II loop conformational flexibility. A loop mutation strategy is then shown to accelerate the conformational transitions and improve the accuracy of FEP binding energy calculations.

**Materials and methods**

**Cross-docking data set**

Cross-docking is a process that computationally fits a compound into a receptor structure solved using another compound as a binding ligand. Self-docking, in contrast, describes the process of docking a native ligand back into its experimentally determined crystal structure after having removed the crystallography resolved ligand. Cross-docking, therefore, represents the typical scenario encountered in discovery research where a ligand is docked into an experimentally determined protein structure (obtained using a different ligand) with the aim of generating a realistic binding pose prediction to support ligand optimization. When the receptor binding pocket is flexible and the new compound is substantially different from the native ligand, large conformational changes in the binding pocket can be expected in binding to the new compound. It was this cross-docking challenge (specifically applied to covalent ligands) that we sought to overcome in the development of FlexCovDock methodology. To illustrate the magnitude of these challenges in the context of the KRAS$^\text{G12C}$ switch-II pocket, we created a cross-docking data set that incorporated ten structurally diverse ligands with crystallographically determined binding poses (see Table 1) and cross- (and self-) docked each of these ligands into each crystallographically determined receptor structure. These ten protein–ligand complexes were selected to cover the wide range of known switch-II binding modes and receptor conformations. Among these ten structures, seven are previously published and three (8DNI, 8DNJ, and 8DNK) are newly reported.

**FlexCovDock workflow**

CovDock is the covalent docking workflow in the Schrödinger Suite that combines Glide small molecule

| Ligand | ARS-853 [40] (1) | ARS-1620 [41] (2) | Sotorasib (AMG 510) [3] (3) | Amgen Cmpd 5 [42] (4) | Adagrasib (MRTX849) [43] (5) |
|---|---|---|---|---|---|
| PDB | 5F2E | 5V9U | 6OIM | 6P8X | 6UT0 |

| Ligand | AstraZeneca Cmpd 25 [44] (6) | Bayer Cmpd 13 [45] (7) | Araxes Cmpd I-1 [46] (8) | AstraZeneca Cmpd 76 [47] (9) | Taiho Cmpd 6 [48] (10) |
|---|---|---|---|---|---|
| PDB | 6T5B | 6TAN | 8DNI | 8DNJ | 8DNK |

All structures determined by X-ray crystallography

[Springer]
docking and Prime protein structure refinement, which has been described previously in detail [20]. Here, we provide a brief summary as an overview: In the first stage of CovDock docking, the target reactive residue is mutated to alanine, and Glide is then used to dock the target ligand into the binding pocket. In the second stage, the reactive residue is mutated back to its original identity, and its side chain rotamer states are enumerated and combined with differing ligand poses from the Glide docking. The protocol then attempts to form covalent bonds between the various reactive residue side chain rotamers and differing Glide-generated ligand poses, rejecting covalent adducts where proper bond geometry cannot be obtained. In the last stage of the protocol, the resulting candidate covalent adduct poses are clustered, refined, and ranked using the Prime energy function.

In FlexCovDock, two key modifications are made to this workflow: (1) residues that severely block the binding site (as discussed below) are mutated to alanine (alongside the target reactive residue) prior to initial Glide docking. These residues are subsequently mutated back to their original identities after the generation of an ensemble of docked poses; (2) in the Prime refinement stage, a binding site refinement protocol is applied which re-packs the side chains of flexible binding site residues and minimizes all atoms of the ligand and binding site residues. This protocol is available in Prime as a function call “siteopt” and the side chain repacking algorithm has been described in a previous publication [25]. A schematic workflow comparison between CovDock and FlexCovDock is shown in Supplementary Information Fig. S1. For the KRASG12C switch-II pocket, the choice of ‘blocking’ residues and ‘flexible’ residues is discussed in the Results and Discussion.

Binding affinity data set

To evaluate binding affinity prediction using docking score, MMGBSA, and FEP, we assembled three sets of compounds (SAR1–3) which probe differing regions of the switch-II binding pocket. SAR1 compounds are taken from Table 1 of Shin, et al. [42], SAR2 compounds are from Table 2 of Lanman, et al. [3], and SAR3 compounds are not published previously, which comprise a set of 14 compounds having the same quinazolinone core as sotorasib (3) and whose N1-substituents interact directly with the switch-II loop. (Co-crystal structures of all 14 of these compounds have been solved internally.) The structures and experimental binding affinities of these compounds are reported in the Supplementary Information (Table S1–S3). Assay conditions for the determination of experimental binding affinities have been described previously [3, 42]. It should be noted that all compounds in our datasets are irreversible covalent inhibitors. The binding affinities (and IC50 values) reported here are not measured at equilibrium but are rather measured at a fixed time point (i.e., five minutes after inhibitor introduction). All compounds within each dataset share the same reactive warhead and are assumed to have approximately the same intrinsic rate of reaction with their target cysteine residues. Thus, differences in binding affinity (at a fixed timepoint) reflect the influence of differing non-covalent protein–ligand interactions (vs. intrinsic warhead reactivity factors) and can be modelled using the various affinity prediction methods employed in this work (e.g., docking score, MMGBSA, and FEP).

Computational setup

All computations were performed with Schrödinger Suite 2020-2 [49]. MMGB scoring was conducted using the Prime VSGB2.0 model [50] and OPLS3e force field [51]. FEP calculations were performed using FEP+ with the force field OPLS3e. Unless otherwise noted, all FEP+ calculations were performed using default settings and 10 ns of simulation. The FlexCovDock workflow was a modified version of CovDock with the Schrödinger Python API. Prior to calculation, all ligands were prepared using LigPrep, and a single tautomer and charge state was chosen based on PROPKA at pH 7.0. All receptor structures were prepared with Protein Preparation Wizard with default settings.

X-ray crystallography

A ‘cysteine-light’ mutant construct was used for co-crystallization studies, based on the work of Ostrem et al. [5]. Purified recombinant human KRASG12C1–169 protein (untagged) in 20 mM HEPES pH 7.5, 150 mM NaCl was concentrated to 40–50 mg/ml, and added to a twofold molar excess of solid compound dissolved in DMSO. The resulting ligand–protein complex was incubated at room temperature for 16 h on a mixer, and subsequently spin-filtered. LC Mass Spectrometry was performed to determine % conjugation of covalently modified sample.

Co-crystallization was performed using the sitting drop vapor diffusion method. Covalent ligand–protein complex samples were mixed 1:1 with crystallization buffer using a Mosquito® robot (SPT Labtech). Crystals appeared within 1 week at 20 °C. KRASG12C complexed to compound 8 crystallized in 0.1 M MES pH 6.5, 30% PEG-4000, 1 mM MgCl2; compound 9 crystallized in 0.1 M MES pH 6.5, 30% PEG-4000, 1 mM MgCl2, 10% EtOH; and compound 10 crystallized in 0.1 M TRIS pH 8.5, 2 M (NH4)2SO4.

All data sets were collected on a Pilatus3 6 M silicon pixel detector at the Advanced Light Source Beamline 5.0.2 at wavelength 1.00000 Å and temperature 100 K. The data were integrated and scaled using either HKL2000 [52] or DIALS [53]. The structures were solved by molecular replacement using Phaser [54] from the CCP4 program.
Results and discussion

Characterization of binding site residue flexibility

Figure 1 illustrates the challenge posed by conventional cross-docking of different ligands with differing receptor structures. As shown, superposition of the ten receptor structures from the cross-docking data set reveals dramatically differing backbone and side chain conformations for the switch-II loop residues (Ala59–Tyr64). The adjacent α2-helix (Ser65–Thr74) likewise demonstrates significant conformational shifts across this set of X-ray structures. This conformational flexibility results in markedly different ligand–receptor interactions in differing X-ray structures.

One particularly stark example of this is associated with the conformationally flexible His95 residue. In 2019, Amgen researchers reported that the His95 residue of KRAS could adopt conformation in which its side chain was oriented away from the switch-II pocket, opening a previously unrecognized ‘cryptic’ pocket [42]. This pocket, which had not previously been exploited by reported covalent KRASG12C inhibitors, was subsequently leveraged in the design of the covalent inhibitor sotorasib [3]. Sotorasib (3) binds to the switch-II pocket region of KRAS by additionally engaging this cryptic sub-pocket, which is revealed in the ‘open’ conformation of His95 (see label, Fig. 1); other ligands, such as ARS-1620 (2), bind instead to a switch-II pocket conformation in which the His95 side chain adopts a ‘closed’ conformation (see Fig. 1).

In addition to His95, a range of other switch-II pocket residues demonstrate differing degrees of ligand engagement across the structures included in the cross-docking data set. Within the switch-II loop, Glu63 and Tyr64 are two prominent examples. Tyr64, for example, while frequently solvent-exposed, can sometimes adopt a pocket-facing conformation and engage in π-stacking interactions with the ligand. Glu63, in contrast, has always been observed to be oriented toward the solvent, and its side chain does not make direct contacts with switch-II pocket ligands in any structures.

Within the α2-helix, Arg68 and Met72 represent two-pocket-facing residues whose flexible side chains have been observed to adopt diverse conformations when complexed to differing switch-II pocket ligands, and whose positioning is additionally impacted by conformational changes in the position and rotation of α2-helix. Further highlighting the high conformational mobility of the switch-II loop, it should be noted that switch-II loop conformation can be significantly influenced by crystal packing interactions [10]. Ligand–receptor interactions can differ substantially between different copies of the same binding site within a single crystallographic unit cell. Additionally, the high flexibility of the switch-II loop frequently prevents the assignment of positions for all residues of the switch-II loop in some x-ray structures.

Blocking residues and flexible residues

The high conformational flexibility of the switch-II pocket posed two chief problems for accurate docking: (1) the need to incorporate multiple switch-II and α2-helix conformations in docking, and (2) the need to accommodate a high degree of side chain flexibility in docking. To successful address these challenges, we found it useful to divide switch-II pocket residues into two classes: (1) residues inside the switch-II pocket that severely impair the cross-docking of another ligand (‘blocking residues’); and (2) flexible peripheral residues that do not severely block the pocket but that can make important ligand–receptor interactions following ligand binding (‘flexible residues’). These residues were initially identified through inspection of the ten structures in the cross-docking data set but were subsequently defined by plotting the side chain χ-1 and χ-2 angle distributions for all binding site residues across a collection of more than 200 internal crystal structures.

Figure 2 shows the torsional angle plots and representative structures for some of the selected residues. We determined the following 26 residues to have high degrees of conformational flexibility and thus to be key residues for conformational sampling and refinement in the FlexCovDock protocol (‘flexible residues’): Thr58–Thr74, Lys88, Asp92, His95, Tyr96, Gln99, Arg102, Val103, Cys12 and Glu37. Five of these residues (Glu62, Tyr64, Arg68, Met72 and His95) were determined to be capable of severely blocking the cross-docking of non-cognate ligands (‘blocking residues’) and were therefore mutated to alanine in the initial stage of FlexCovDock. The side chains of all flexible residues (including blocking residues) are repacked, and the backbone atoms are minimized in FlexCovDock workflow. This protocol limits the extent to which it is necessary to sample backbone conformational
space. While incorporating loop prediction into the FlexCovDock protocol (e.g., using Prime loop prediction [26, 50]) could allow for larger switch-II loop movements, loop prediction is computationally expensive, and limited testing of such a workflow did not provide significantly improved docking accuracy.

**Binding pose prediction**

Figure 3 shows one example of the cross-docking of sotorasib (3) using the ARS-1620 (2) receptor structure (PDB 5V9U). In the ARS-1620 structure (Fig. 3A, green), the His95 side chain adopts a ‘closed’ conformation with the His95 side chain oriented toward the switch-II pocket, a

---

**Fig. 2** Side chain torsion angle distributions and representative structures for selected residues in the switch-II pocket. (Plots represent data from > 200 KRAS crystal structures.)

**Fig. 3** Comparison of the FlexCovDock-predicted binding modes of sotorasib (3) in the ARS-1620 (2) receptor and experimental structure. **A** superposition of the sotorasib (3; gray) and ARS-1620 (2; green) X-ray structures (PDB 6OIM & 5V9U, respectively). **B** predicted sotorasib pose using the ARS-1620 receptor (green, 0.8 Å RMSD) as compared with the crystallographically determined structure of sotorasib bound to KRAS\textsuperscript{G12C} (gray)
conformation which would prevent the successful docking of sotorasib (3). In the FlexCovDock prediction (Fig. 3B, green), His95 was correctly moved to the ‘open’ conformation. As a result, the predicted top sotorasib (3) binding pose had only an 0.8 Å RMSD relative to the crystallographically observed binding pose. In contrast, the top binding pose identified using the conventional CovDock protocol demonstrated a 5.2 Å RMSD. Interestingly, except for His95, FlexCovDock did not predict all other side chains identically to their crystallographically determined positions (cf. Arg68, Fig. 3B), nor did it move the switch-II loop closer to the crystallographically determined position (cf. green and grey structures, Fig. 3B). It’s notable that relatively reasonable side chain conformational predictions alone were sufficient to enable correct ligand pose prediction—high precision side chain pose predictions were not required.

To further benchmark the performance of FlexCovDock, we collected ten co-crystal structures of structurally diverse ligands demonstrating conformationally diverse switch-II pocket poses. We then docked each ligand into every receptor structure, leading to a set of 100 docking simulations (10 self-docking and 90 cross-docking). (In the following paragraphs, we make no distinction between self- and cross-docking models, so ‘cross-docking’ should be understood to include these ten self-docking examples.) Comparing CovDock to the modified FlexCovDock protocol, in the 10 self-docking cases, CovDock correctly predicted the docked ligand pose to within a heavy atom RMSD of 2.0 Å in all cases. FlexCovDock, by comparison, correctly predicted 9/10 ligand poses to within 2.0 Å RMSD and 10/10 poses to within 2.5 Å RMSD (see Supplementary Table S5 and S6).

Figure 4 compares the performance of CovDock and FlexCovDock across all 100 cross-docking jobs. As seen, FlexCovDock significantly improved the accuracy of binding pose prediction across a wide range of differing RMSD cutoffs and ranking criteria. For example, using RMSD 2.0 Å as a cutoff and focusing on the top-ranked pose for each docking job, FlexCovDock correctly predicted the ligand pose in 46 cases, whereas CovDock was only successful in 27 cases. Focusing instead upon the best pose identified amongst the top 20 poses identified by each protocol, FlexCovDock correctly predicted the crystallographic binding pose 89% of the time, whereas CovDock was only successful 55% of the time.

Prospective prediction in challenging cases

These 100 cross-docking cases were designed to model the very challenging case where a novel compound is identified which induces large structural change in a known receptor structure. Such cases can arise, for instance, when novel hit compounds are identified in a screening campaign or when new ligands emerging in the literature that are highly structurally distinct from historical ligands. As an illustration of the former situation, we have had the opportunity to test FlexCovDock prospectively on a set of four novel compounds whose X-ray crystal structures were only solved subsequently to modeling (internal data). In all four cases, the FlexCovDock-predicted ligand binding poses were predicted with less than 2.5 Å RMSD from the crystallographic pose and with average RMSD of 1.3 Å.

Customization of flexible regions

FlexCovDock has also worked well in cases where only small changes were made to ligands with known co-crystal structure. One common issue with flexible receptor docking is that dramatic movements in receptor residues can be observed, leading to unexpected (and inaccurate) docking results. Despite allowing full receptor flexibility in the binding site, FlexCovDock has proven resistant to such challenges, working well across all ten of the aforementioned self-docking cases, thanks to the accurate side chain packing algorithm and energy function in Prime protein structure modeling. In practice, binding site flexibility can be customized for optimal performance in the FlexCovDock workflow by changing the list of ‘blocking residues’ and ‘flexible residues.’ For example, when focused changes are made to a specific region of a ligand, the flexible residue list can be tailored to include only those residues that interact with this region of the ligand. We have found that making such tailored changes can often lead to better pose prediction accuracy. The blocking residues can have substantial impact to the prediction accuracy. Supplementary Information Table S5 shows the results of using 4, 5, and 6 blocking residues in the cross-docking data set. We chose five blocking residues because it was the minimum set of residues that cover potential major side chain conformational changes across the docked ligands.
Binding affinity prediction

As previously mentioned, the high conformational flexibility of the switch-II pocket also poses a great challenge to the accurate prediction of binding affinities. Here, we investigate the prediction of ligand binding affinities with three different methods, docking score, MMGB, and FEP+, using three group of compounds chosen to probe different portions of the switch-II pocket and to represent differing levels of ligand and receptor flexibility. Figure 5 shows these three groups of compounds (SAR1, 2, & 3) and their respective binding pockets.

SAR1 and SAR2 compounds make close receptor contacts within the His95 pocket [3]. SAR1 comprises ligands that contact the β-carbon of the His95 side chain as well as the Tyr96 side chain. SAR2, in contrast, contains compounds that make broader contacts with the His95-pocket and engage in π-stacking interactions with the His95 side chain. SAR3 compounds engage in direct interactions with residues in the switch-II loop. Based on the conformational flexibility of the switch-II pocket and the compounds within

![Fig. 5 Overview of the binding modes of three group of compounds (SAR1–3) and their binding affinity predictions by docking score, MMGB, and FEP+. SAR1 compounds (leftmost column) have the least ligand and receptor flexibility and are predicted well by all methods. (The top-left image shows the aligned compounds in the 6OIM crystal structure.) SAR2 compounds (middle column) demonstrate significant ligand conformational flexibility but are bound to a common switch-II pocket pose. Binding affinities for these ligands are only predicted well by FEP+. (The top-middle image shows the aligned compounds in the 6P8X crystal structure.) SAR3 compounds (rightmost column) induce conformational changes in the switch-II loop and are challenging to model by all methods. (The top-right image shows the superposition of all 14 cocrystal structures in the group.) Modification of FEP+ protocol (as described here) significantly improved the prediction accuracy for SAR3 (orange correlation line).](image-url)
each SAR group, we can characterize these three SAR groups as ‘rigid receptor, rigid ligand’ (SAR1), ‘rigid receptor, flexible ligand’ (SAR2), and ‘flexible receptor, flexible ligand’ (SAR3), respectively.

Both docking score and MMGB calculations were performed using poses generated by the FlexCovDock protocol. SAR1 and SAR3 compounds were docked using the 6OIM crystal structure and SAR2 compounds were docked using the 6P8X crystal structure, as these crystal structures contained the most similar ligands to these sets of compounds. For FEP+ calculations, simulations started from 6OIM (SAR1 and SAR3) and 6P8X (SAR2); all ligands were structurally aligned to the crystallographic ligand.

As shown in Fig. 5, all binding affinity prediction methods perform well for SAR1 (which represents a relatively easy case, given both rigid receptor and ligands). Although His95 can adopt both open- and closed-conformations, all compounds within this group bind to an ‘open’ His95 receptor pose. For the SAR2 group, docking score and MMGB binding affinities have weak correlations with experimental binding affinities, however FEP+ still performs well, with excellent R² and mean unsigned error (MUE). This, too, is understandable, given how the ligand flexibility of these SAR2 compounds is handled by these methods. Scoring methods using a single, static structure such as docking and MMGB cannot capture conformational dynamics and entropic contributions to binding affinity, whereas FEP+ can encompass these factors by sampling the motion of these flexible ligands in their binding pocket.

For SAR3, all methods performed very poorly. This represents the most challenging case for binding energy prediction, as these ligands interact with a highly flexible receptor (switch-II loop), and induce multiple different conformations (as shown in crystal structures above). One interesting question is, can we obtain better results using the co-crystal structure of each individual ligand in the affinity scoring instead of the docked poses? FEP+ requires a single receptor structure in the calculation for the group of compounds, so it is unclear how to use multiple crystal structures. For docking score and MMGB calculations, scoring with each crystal structure did not show any improvement in the R² values (data not shown).

### Slow convergence of FEP+ on switch-II loop conformational change

We suspected that the poor performance of FEP+ with SAR3 compounds was due to difficulties in sampling switch-II loop conformations. One pair of compounds, compounds 11 and 12 from SAR3 (compound 11 and 13 in SI Table S3, respectively), was chosen for a detailed study. The experimental relative binding affinity difference between these two compounds was 0.06 kcal/mol, however FEP+ predicted their relative difference in binding affinity (ΔΔG) as −2.52 kcal/mol using 6OIM receptor.

As shown in Fig. 6A, in the 6OIM structure, Glu63 severely clashes with one isopropyl group in compound 12 in its binding pose extracted from its cognate crystal structure. Although compounds 11 and 12 have very similar switch-II loop conformations, these loop conformations differ significantly from that that observed in 6OIM. In the experimental X-ray structures of these two ligands, the backbone atom positions of residues Gln61, Glu62, and Glu63 are close to the positions of Glu62, Glu63, and Tyr64 of 6OIM, respectively. While this backbone conformational difference may appear small, it results in multiple backbone torsional angle changes that would take a very long time to access during an MD simulation.

Figure 6B illustrates FEP+ prediction of the binding affinity differences between compounds 11 and 12 using the

---

Fig. 6 Switch-II loop conformational changes lead to slow convergence of FEP+: targeted protein mutations improve the accuracy. A The crystal structures of compound 11 (pink) and compound 12 (green). The 6OIM receptor structure is shown in gray and displays backbone atom clashes with both ligands. (Note: the positions of E63 and E62 in 6OIM are shifted relative to the corresponding residues in the compound 11 and 12 X-ray structures.) B and C FEP+ prediction of binding affinity differences (ΔΔG) between compounds 11 and 12 using different receptor structures and simulation times. The experimental ΔΔG between compound 11 and 12 is 0.06 kcal/mol

© Springer
6OIM receptor (red line) and the crystallographically determined compound 12 receptor structure (green line). When simulation started using the compound 12 receptor structure (with correct switch-II loop conformation), FEP+ was able to accurately predict the experimental difference in binding affinity within 5 ns. (Longer simulation demonstrated that the MD trajectory had already converged.) Starting from the 6OIM receptor structure (where the switch-II loop initially clashes with compound 12), the predicted binding affinity gradually improved with increasing simulation time, from −2.52 kcal/mol at 5 ns to −1.05 kcal/mol at 160 ns.

Although the study of this pair of compounds shows that FEP+ can achieve accurate binding affinity estimates and overcome incorrect starting conformations in the switch-II loop, doing so requires very long simulation times, making this brute-force approach impractical both in terms of computing cost and turnaround times.

**Loop mutation strategy**

To overcome these issues, we developed a new strategy that both significantly accelerated the convergence of FEP+ calculations while also achieving enhanced accuracy. In this strategy, we mutated residues Glu62, Glu63, Tyr64 and Glu76 to glycine and used the mutated receptor structure in the FEP+ calculation. The rationale was as follows: (1) with these mutations, the backbone conformational transition in MD would be much faster, and (2) these residues do not have side chain contact with the ligands; thus, these mutations would not have large impacts on the relative binding affinity of these ligands. Note that Glu76 is at the end of α2-helix and does not belong to switch-II pocket. The mutation of glutamate 76 to glycine (E76G) created a segment of 3 consecutive glycines (with Gly75 and Gly77), which increased the mobility of the α2-helix. This mutation was not necessary for this specific pair of compounds 11 and 12 (see Supplementary Information Table S7), but we included it in the mutated structure because it was beneficial when the ligands caused significant movement of α2-helix as we encountered in our internal project.

Figure 6C shows the improved FEP+ accuracy with faster convergence using this loop mutation strategy. Using the mutated 6OIM receptor, 5 ns FEP+ simulation already showed a greatly improved predicted ΔΔG (−1.05 vs. −2.82 kcal/mol), and 20 ns of FEP+ further improved the ΔΔG to −0.27 kcal/mol (orange line). Comparing the resulting ΔΔG to that obtained using the native compound 12 receptor structure (−0.03 kcal/mol, green line), it is apparent that this mutation strategy did not significantly alter the calculated binding affinity, as expected.

To investigate the necessity of proper conformational sampling of the switch-II loop in generating an accurate binding affinity calculation, we also examined minimization of the 6OIM structure while holding the aligned compound 12 fixed in the pocket prior to FEP+ calculation. The results obtained using the minimized 6OIM receptor were not much better than those obtained using the original (unminimized) 6OIM structure (purple line, Fig. 6C). This showed that a simple minimization to relieve the steric clash between ligand and the receptor was insufficient to improve binding energy predictions, and that the proper backbone conformational transition was required for accurate FEP+ binding energy prediction. Finally, we used the mutated 6OIM structure for FEP+ calculations for all 14 compounds in SAR3. Using this approach, the MUE was improved from 1.44 to 0.89 kcal/mol, as shown in Fig. 5.

**Conclusions**

The high receptor flexibility of the KRAS switch-II pocket presents a challenge to current state-of-the-art methods for binding pose and binding affinity prediction. In this work, we report a modification of the CovDock workflow to incorporate receptor flexibility, enabling the accurate binding pose prediction of ligands which induce large conformational changes in the ligand binding site. We have validated this protocol using a large cross-docking data set and have used this methodology to successfully optimize multiple switch-II pocket-targeted inhibitors of KRAS<sup>G12C</sup>. Although we illustrate this protocol in the refinement of covalent inhibitors for KRAS<sup>G12C</sup>, it should be noted that this methodology should also prove extensible to the modeling of covalent inhibitors of other flexible proteins.

We additionally report refinements to FEP+ based binding affinity prediction methods that facilitate binding energy predictions with conformationally flexible receptors. In the case of KRAS<sup>G12C</sup> inhibitor binding affinity prediction, we show that compounds that directly engage the conformationally dynamic switch-II loop pose the greatest challenge. Structurally diverse inhibitors can induce differing switch-II loop conformations that FEP+ can take a very long time to sample. We have shown that mutating a small number of residues within and near the switch-II loop can greatly improve the accuracy of FEP+ without requiring significantly lengthened simulation time. This strategy has its limitations, however, and relies on the assumption that the side chains of the mutated residues do not make strong contacts with the ligands. Caution should be exercised when this assumption may be in doubt.

Receptor flexibility presents a major challenge for the accurate forecasting of protein–ligand binding for many pharmaceutically relevant targets. The efficient sampling of protein backbone conformational changes and accurate calculation of protein reorganization energies remain an important unsolved problem for the future research. The
strategy presented in this work to address the conformational flexibility of switch-II loop, although not a universal solution, should prove useful in other similar situations.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s10822-022-00467-0.

Acknowledgements We would like to thank Crystallographic Consulting, LLC and the Advanced Light Source staff at beamline 5.0.2 for their data collection support. The Berkeley Center for Structural Biology is supported in part by the National Institutes of Health, National Institute of General Medical Sciences, and the Howard Hughes Medical Institute. The Advanced Light Source is supported by the Director, Office of Science, Office of Basic Energy Sciences, of the U.S. Department of Energy under Contract No. DE-AC02-05CH11231. KZ would like to thank Huan Rui and Yax Sun for helpful discussions.

Author contributions The manuscript was written with the contribution of all authors.

Funding All authors are current or former employees of Amgen Inc., which provided financial support for this work.

Data availability All the data generated in this work is freely available in the supplementary information or by contacting the corresponding author. Three new crystal structures, 8DNI, 8DNJ, and 8DNK, have been deposited to PDB.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Cox AD, Der CJ (2010) Ras history: the saga continues. Small GTPases 1:2–27
2. Der CJ, Krontiris TG, Cooper GM (1982) Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses. Proc Natl Acad Sci USA 79:3637–3640
3. Lanman BA, Allen JR, Allen JG, Amegadzie AK, Ashton KS, Booker SK, Chen JJ, Chen N, Frohn MJ, Goodman G, Kopecky DJ, Liu L, Lopez P, Low JD, Ma V, Minatti AE, Nguyen TT, Nishimura N, Pickrell AJ, Reed AB, Shin Y, Siegmund AC, Tamayo NA, Tegley CM, Walton MC, Wang HL, Wurz RP, Xue M, Yang KC, Achanta P, Barberger MD, Canon J, Hollis LS, Mccarter JD, Mohr C, Rex K, Saiyi AS, Yang M, Rapaport AS, San Miguel T, Ortiz R, Osgood T, Sun JR, Zhu X, McCarther JD, Volak LP, Houk BE, Fakih MG, O’Neil BH, Price TJ, Falchook GS, Desai J, Kuo J, Govindan R, Hong DS, Ouyang W, Henary H, Arvedson T, Cee VJ, Lipford JR (2019) The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 575:217–223
4. Canon J, Rex K, Saiyi KY, Mohr C, Cooke K, Bagal D, Gaida K, Holt T, Knutson CG, Koppada N, Lanman BA, Werner J, Rapaport AS, San Miguel T, Ortiz R, Osgood T, Sun JR, Zhu X, McCarther JD, Volak LP, Houk BE, Fakih MG, O’Neil BH, Price TJ, Falchook GS, Desai J, Kuo J, Govindan R, Hong DS, Ouyang W, Henary H, Arvedson T, Cee VJ, Lipford JR (2019) The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 575:217–223
5. Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM (2013) K-Ras (G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503:548–551
6. Grant BJ, Lukman S, Hocker HJ, Sayyah J, Brown JH, McCammon JA, Gorfe AA (2011) Novel allosteric sites on Ras for lead generation. PLoS ONE 6:e25711
7. Wang W, Fang G, Rudolph J (2012) Ras inhibition via direct Ras binding—is there a path forward? Bioorg Med Chem Lett 22:5766–5776
8. Singh J, Petter RC, Bailie TA, Whitty A (2011) The resurgence of covalent drugs. Nat Rev Drug Discov 10:307–317
9. Xu Q, Zhang G, Liu Q, Li S, Zhang Y (2022) Inhibitors of the GTPase KRAS(G12C) in cancer: a patent review (2019–2021). Expert Opin Ther Pat 32(5):475–505
10. Pantasar T (2020) The current understanding of KRAS protein structure and dynamics. Comput Struct Biotechnol J 18:189–198
11. Aantunes DA, Devaurs D, Kawraki LE (2015) Understanding the challenges of protein flexibility in drug design. Expert Opin Drug Discov 10:1301–1313
12. Buonongiro R, Recanatini M, Masetti M (2015) Protein flexibility in drug discovery: from theory to computation. ChemMedChem 10:1141–1148
13. Evangelista Falcon W, Ellingson SR, Smith JC, Baudry J (2019) Ensemble docking in drug discovery: how many protein configurations from molecular dynamics simulations are needed to reproduce known ligand binding? J Phys Chem B 123:5189–5195
14. Amaro RE, Baudry J, Chodera J, Demir O, McCammon JA, Miao Y, Smith JC (2018) Ensemble docking in drug discovery. Biophys J 114:2271–2278
15. Kamenik AS, Singh I, Lak P, Balus TE, Liedl KR, Shoichet BK (2021) Energy penalties enhance flexible receptor docking in a model cavity. Proc Natl Acad Sci USA. https://doi.org/10.1073/pnas.2106195118
16. Ravindranath PA, Forl, S, Goosdell DS, Olson AJ, Sanner MF (2015) AutoDockFR: advances in protein-ligand docking with explicitly specified binding site flexibility. PLoS Comput Biol 11:e1004586
17. Sherman W, Day T, Jacobson MP, Friesner RA, Farid R (2006) Novel procedure for modeling ligand/receptor induced fit effects. J Med Chem 49:534–553
18. Miller EB, Murphy RB, Sindikara D, Borrelli KW, Grisewood MJ, Ranalli F, Dixon SL, Jerome S, Boyles NA, Day T, Ghanakota MJ, Mondal S, Rafi SB, Troast DM, Abel R, Friesner RA (2021) Reliable and accurate solution to the induced fit docking problem for protein-ligand binding. J Chem Theory Comput 17:2630–2639
19. Scarpino A, Ferenczy GG, Keseru GM (2020) Covalent docking–is there a path forward? Bioorg Med Chem Lett 30:52–65
20. Miller EB, Murphy RB, Sindikara D, Borrelli KW, Grisewood MJ, Ranalli F, Dixon SL, Jerome S, Boyles NA, Day T, Ghanakota MJ, Mondal S, Rafi SB, Troast DM, Abel R, Friesner RA (2021) Reliable and accurate solution to the induced fit docking problem for protein-ligand binding. J Chem Theory Comput 17:2630–2639
21. Sherman W, Day T, Jacobson MP, Friesner RA, Farid R (2006) Novel procedure for modeling ligand/receptor induced fit effects. J Med Chem 49:534–553
22. Miller EB, Murphy RB, Sindikara D, Borrelli KW, Grisewood MJ, Ranalli F, Dixon SL, Jerome S, Boyles NA, Day T, Ghanakota MJ, Mondal S, Rafi SB, Troast DM, Abel R, Friesner RA (2021) Reliable and accurate solution to the induced fit docking problem for protein-ligand binding. J Chem Theory Comput 17:2630–2639
23. Scarpino A, Ferenczy GG, Keseru GM (2020) Covalent docking–is there a path forward? Bioorg Med Chem Lett 30:52–65
hydrophobic enclosure for protein-ligand complexes. J Med Chem 49:6177–6196

23. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shelley M, Perry JK, Shaw DE, Francis P, Shenkin PS (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47:1739–1749

24. Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, Pollard WT, Banks JL (2004) Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 47:1750–1759

25. Zhu K, Shirts MR, Friesner RA (2007) Improved methods for side chain and loop predictions via the protein local optimization program: variable dielectric model for implicitly improving the treatment of polarization effects. J Chem Theory Comput 3:2108–2119

26. Zhu K, Pincus DL, Zhao S, Friesner RA (2006) Long loop prediction using the protein local optimization program. Proteins 65:438–452

27. London N, Miller RM, Krishnan S, Uchida K, Irwing JJ, Eiad O, Gobid L, Cimermanic P, Bonnet R, Shoichet BK, Taunton J (2014) Covalent docking of large libraries for the discovery of chemical probes. Nat Chem Biol 10:1066–1072

28. Bitencourt-Ferreir G, Pintro VO, de Azevedo WFJR (2019) Docking with autodock4. Methods Mol Biol 2053:125–148

29. Ouyang X, Zhou S, Su CT, Ge Z, Li R, Kwoh CK (2013) Covariant series. J Chem Inf Model 51:2082–2089

30. Scarpino A, Petri L, Knez D, Imre T, Abranyi-Balogh P, Ferenczy GG, Gobec S, Keseru GM (2021) WIDOCK: a reactive docking protocol for virtual screening of covalent inhibitors. J Comput Aided Mol Des 35:223–244

31. Rachman M, Scarpino A, Bajusz D, Palfy G, Vida I, Perczel A, Barril X, Keseru GM (2019) DUckCov: a dynamic undocking-based virtual screening protocol for covalent binders. ChemMedChem 14:1011–1021

32. Schroder J, Klinger A, Oellien F, Marhofer RJ, Duszenko M, Selzer PM (2013) Docking-based virtual screening of covalently binding ligands: an orthogonal lead discovery approach. J Med Chem 56:1478–1490

33. Pantzar T, Poso A (2018) Binding affinity via docking: fact and fiction. Molecules 23(8):1899

34. Song LF, Lee TS, Zhu C, York DM, Merz KMJR (2019) Using AMBER18 for relative free energy calculations. J Chem Inf Model 59:3128–3135

35. Pu C, Yan G, Shi J, Li R, Knez D, Sabet S, Saiki AY, Sawamata A, Sethofer S, Tegley CM, Volak LP, Yang K, Lanman BA, Erlanson DA, Cee VJ (2019) Discovery of N-(1-Acryloylazetidin-3-yl)-2-(1H-indol-1-yl) acetamides as covalent inhibitors of KRAS(G12C). ACS Med Chem Lett 10:1302–1308

36. Fell JB, Fischer JP, Baer BR, Blake JF, Bouhanna K, Briere DM, Brown KD, Burgess LE, Burns AC, Burkard MR, Chiang H, Chiarelli MJ, Cook AW, Gaudino JJ, Hallin J, Hanson L, Hartley DP, Hicken EJ, Hingorani GP, Inkinson R, Mejia MJ, Olson P, Otten JN, Rhodes SP, Rodriguez ME, Savechenkov P, Smith DJ, Sudhakar N, Sullivan FX, Tang TP, Vigers GP, Wollenberg L, Christensen JG, Marx MA (2020) Identification of the clinical development candidate MRTX849, a covalent KRAS(G12C) inhibitor for the treatment of cancer. J Med Chem 63:6679–6693

37. Kettle JG, Bagal SK, Bickerton S, Bodnarchuk MS, Breed J, Carbajo RJ, Cassar DJ, Chakraborty A, Cosulich S, Cummings I, Davies M, Eatherton A, Evans L, Feron L, Gleave M, Goldberg FW, Harlfinger S, Hanslon B, Hendry J, Howells R, Jackson A, Kemmitt P, Kingston JK, Lamont S, Lewis HJ, Li S, Liu L, Ogg D, Phillips C, Polanski R, Robb G, Robinson D, Ross S, Smith JM, Tonge M, Whiteley R, Yang J, Zhang L, Zhao X (2020) Structure-based design and pharmacokinetic optimization of covalent allosteric inhibitors of the mutant GTPase KRAS(G12C). J Med Chem 63:4486–4483

38. Mortier J, Friberg A, Badock V, Moosmayer D, Schroeder J, Steigemann P, Siegel F, Gradl S, Bauser M, Hillig RC, Briem H, Eis K, Bader B, Nguyen D, Christ CD (2020) Computationally empowered workflow identifies novel covalent allosteric binders for KRAS(G12C). ChemMedChem 15:827–832

39. Li L, Feng J, Wu T, Liu Y, Wang Y, Baur M, Cassar D, Pike K (2020) Fused tricyclic compounds useful as anticancer agents. WO 2020028706 A1

40. Kuhn D (2020) Large-scale assessment of binding free energy calculation protocol and force field. J Am Chem Soc 137:2695–2703

41. Schindler CEM, Baumann H, Blum A, Bose D, Buchstaller HP, Burgdorf L, Cappel D, Chekrer E, Czodrowski P, Dorsch D, Eguida MKI, Follows B, Fuchss T, Gradler U, Gunera J, Johnson T, Jorand Lebrun C, Karra S, Klein M, Knehas T, Koetzer L, Krier M, Leenendecker M, Leuthner B, Li L, Mochalkin I, Musil D, Neagu C, Rippmann F, Schiemann K, Schulz R, Steinbrecher T, Tanzer EM, Unzue Lopez A, Viacava Follis A, Wegener A, Kuhn D (2020) Large-scale assessment of binding free energy calculations in active drug discovery projects. J Chem Inf Model 60:5457–5474

42. Patricelli MP, Janes MR, Li LS, Hansen R, Peters U, Kessler LV, Chen Y, Kucharski JM, Feng J, Ely T, Chen HJ, Fridaas SJ, Babar A, Ren P, Liu Y (2016) Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state. Cancer Discov 6:316–329

43. Janes MR, Zhang J, Li LS, Hansen R, Peters U, Guo X, Chen Y, Babar A, Fridaas SJ, Darjania L, Feng J, Chen HJ, Li S, Li S, Long YO, Thach C, Liu Y, Zarieh A, Ely T, Kucharski JM, Kessler LV, Wu T, Yu K, Wang Y, Yao Y, Deng X, Zarrinkar PP, Brehmer D, Dhanak N, Lorentzi MV, Hu-Lowe D, Patricelli MP, Ren P, Liu Y (2018) Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor. Cell 172(578–589):e17

44. Shin Y, Jeong JW, Wurz RP, Achanta P, Arvedson T, Bartberger MD, Campuzano IDG, Fucini R, Hansen SK, Ingersoll J, Iwag IS, Lipford JR, Ma V, Kohpecky DJ, McCarter J, San Miguel T, Mohr C, Sabet S, Saiki AY, Sawamata A, Sethofer S, Tegley CM, Volak LP, Yang K, Lanman BA, Erlanson DA, Cee VJ (2019) Discovery of N-(1-Acryloylazetidin-3-yl)-2-(1H-indol-1-yl) acetamides as covalent inhibitors of KRAS(G12C). ACS Med Chem Lett 10:1302–1308

45. Fell JB, Fischer JP, Baer BR, Blake JF, Bouhanna K, Briere DM, Brown KD, Burgess LE, Burns AC, Burkard MR, Chiang H, Chiarelli MJ, Cook AW, Gaudino JJ, Hallin J, Hanson L, Hartley DP, Hicken EJ, Hingorani GP, Inkinson R, Mejia MJ, Olson P, Otten JN, Rhodes SP, Rodriguez ME, Savechenkov P, Smith DJ, Sudhakar N, Sullivan FX, Tang TP, Vigers GP, Wollenberg L, Christensen JG, Marx MA (2020) Identification of the clinical development candidate MRTX849, a covalent KRAS(G12C) inhibitor for the treatment of cancer. J Med Chem 63:6679–6693

46. Kettle JG, Bagal SK, Bickerton S, Bodnarchuk MS, Breed J, Carbajo RJ, Cassar DJ, Chakraborty A, Cosulich S, Cummings I, Davies M, Eatherton A, Evans L, Feron L, Gleave M, Goldberg FW, Harlfinger S, Hanslon B, Hendry J, Howells R, Jackson A, Kemmitt P, Kingston JK, Lamont S, Lewis HJ, Li S, Liu L, Ogg D, Phillips C, Polanski R, Robb G, Robinson D, Ross S, Smith JM, Tonge M, Whiteley R, Yang J, Zhang L, Zhao X (2020) Structure-based design and pharmacokinetic optimization of covalent allosteric inhibitors of the mutant GTPase KRAS(G12C). J Med Chem 63:4486–4483

47. Mortier J, Friberg A, Badock V, Moosmayer D, Schroeder J, Steigemann P, Siegel F, Gradl S, Bauser M, Hillig RC, Briem H, Eis K, Bader B, Nguyen D, Christ CD (2020) Computationally empowered workflow identifies novel covalent allosteric binders for KRAS(G12C). ChemMedChem 15:827–832

48. Li L, Feng J, Wu T, Liu Y, Wang Y, Baurm AK, Ren P, Liu Y (2019) Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer. WO2020028706 A1

49. Kettle J, Simpson I, Phillips C, Boyd S, Steward O, Bodnarchuk M, Cassar D, Pike K (2020) Fused tricyclic compounds useful as anticancer agents. WO2020178282 A1

50. Sakamoto T, Kazuno H, Sugimoto T, Kondo H, Yamamoto T (2019) Novel indazole compound or salt thereof. WO2020085493 A1
49. Schrödinger Molecular Modeling Suite, Release 2020-2, Schrödinger, Inc. 1540 Broadway, 24th Floor, New York, NY 10036.

50. Li J, Abel R, Zhu K, Cao Y, Zhao S, Friesner RA (2011) The VSGB 2.0 model: a next generation energy model for high resolution protein structure modeling. Proteins 79:2794–2812

51. Roos K, Wu C, Damm W, Reboul M, Stevenson JM, Lu C, Dahlgren MK, Mondal S, Chen W, Wang L, Abel R, Friesner RA, Harder ED (2019) OPLS3e: extending force field coverage for drug-like small molecules. J Chem Theory Comput 15:1863–1874

52. Otwinowski Z, Minor W (1997) Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 276:307–326

53. Winter G, Waterman DG, Parkhurst JM, Brewster AS, Gildea RJ, Gerstel M, Fuentes-Montero L, Vollmar M, Michels-Clark T, Young ID, Sauter NK, Evans G (2018) DIALS: implementation and evaluation of a new integration package. Acta Crystallogr D Struct Biol 74:85–97

54. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ (2007) Phaser crystallographic software. J Appl Crystallogr 40:658–674

55. Winn MD, Ballard CC, Cowtan KD, Dodson EJ, Emsley P, Evans PR, Keegan RM, Krissinel EB, Leslie AG, McCoy A, McNicholas SJ, Murshudov GN, Pannu NS, Potterton EA, Powell HR, Read RJ, Vagin A, Wilson KS (2011) Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol Crystallogr 67:235–242

56. Murshudov GN, Skubak P, Lebedev AA, Pannu NS, Steiner RA, Nicholls RA, Winn MD, Long F, Vagin AA (2011) REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr D Biol Crystallogr 67:355–367

57. Emsley P, Cowtan K (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60:2126–2132

58. Schuttelkopf AW, van Aalten DM (2004) PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr D Biol Crystallogr 60:1355–1363

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.